If you have been reading about preclinical model and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Muscle biopsy (removes a small piece of muscle tissue, usually from the thigh, to check for dystrophin in muscle cells.) Creatine kinase test (checks the level of Creatine Kinase proteins in the blood. Creatine Kinase proteins are normally found inside of healthy muscle cells, but can be found in the blood when muscle cells are damaged.) Electromyography (shows that weakness is caused by the destruction of muscle tissue rather than by damage to nerves.) Genetic testing (looks for deletion, duplication, or mutation of the dystrophin gene.)
==== Compilations ==== "Bee Sting" - The Thing That Ate Floyd - (Lookout! Records, 1988) "We Walk" - Surprise Your Pig - A Tribute to R.E.M. - (Staple Gun Records, 1992) "Chemical Warfare" - Virus 100 - (Alternative Tentacles, 1992) "Down All the Days" - The Mission District: 17 Reasons - 7" Box (Mission Merchants, 1992) "Kung Fu Love" - Milk for Pussy - (Mad Queen Records, 1993) "Froggie Would a Wooing Go" - Power Flush - as "Mud Bath" with Mudwimmin - (Broken Rekids, 1993) "The Seventh Hour of the Seventh Day" - Smitten - A Love Song Compilation - (Karate Brand Records, 1994) "A Washed Out Monkey Star Halo" - Dope-Guns-'N-Fucking In The Streets Volume Ten - (Amphetamine Reptile Records, 1994) "The 500 Club" - CMJ New Music August - Volume 24 - (College Music Journal, 1995) "Twist" - Introducing Vol. 2 - (Indigo, 1995) "Twist" - London Records (London Records, 1995) "The Charm" - Jabberjaw... Pure Sweet Hell - (Mammoth, 1996) "The Ghost" - Twisted Willie - (Justice Records, 1996) "A Washed Out Monkey Star Halo" - Dope-Guns-'N-Fucking In The Streets Volumes 8-11 - (Amphetamine Reptile Records, 1997) "Soul Cannon" - Live at Emo's BOX SET - 7" Box (No Lie Music, 1997) "I Dreamed I Dream" - Confuse Yr Idols (A Tribute To Sonic Youth) (Narnack Records, 2004)
The following years, she acted in a various European movies, notable A Soul Split in Two (1993), Neuf mois (1994), Un eroe borghese (1995), Vatel (2000), and Two Brothers (2004). On television, she played Catherine Barneville in the comedy series, Call My Agent! (2015–18), and starred as a lead character in the detective series, Agathe Koltès (2016–19). In 2020, she began starring as Sylvie Grateau in the Netflix comedy-drama series, Emily in Paris. In 2022, she appeared as Monique Ritz, widow of Charles Ritz in the episode of Netflix period drama series, The Crown. In April 2025, Leroy-Beaulieu was announced as a brand ambassador for L'Oréal Paris’ Age Perfect Collagen Expert skin-care line in France, part of the company’s campaign to promote “ageless beauty”. Philippine Leroy-Beaulieu has a daughter named Taïs with her partner, director Richard Bean.
Sources: en.wikipedia.org
When BRI1 is silenced in tomato, the plants have a similar phenotype to cu3 mutants yet are still able to respond normally to systemin, strengthening the view that BRI1 is not the systemin receptor. In 1994, tomato systemin was found to bind to a 50KDa protein in the cell membrane of tomato. The protein has a structure similar to proteases of the Kex2p-like prohormone convertases. This led Schaller and Ryan to suggest that it is not a receptor, but instead is involved in the processing of ProSys into the active form, or the degradation of Sys. Synthetic forms of tomato systemin, with substituted amino acids at the predicted dibasic cleavage site, remained stable in cell cultures for longer than the native form. Later studies have noted that the enzymes responsible for processing ProSys remain unidentified. No further research has been reported on the 50KDa protein to date, and the gene has not been identified. No receptors for HypSys have so far been reported, but it is thought that they are perceived on the cell membrane by a LRR-RLK. The receptor for AtPep1 has been identified as a 170KDa LRR-RLK and has been named AtPEPR1. AtPep1 is active at 0.1 nano-molar (nM) concentrations and the receptor saturates at 1nM. An analysis of the structure of the AtPEPR1 receptor has shown that it is a member of the LRR XI subfamily of LRR-RLKs in A. thaliana which includes the receptor for another peptide hormone CLAVATA3. Transforming tobacco cell cultures with AtPEPR1 allowed them to respond to AtPep1 in an alkalisation assay, whereas normal tobacco did not show such a response.
Of the 240 planes that were launched for the strike, 14 aborted for various reasons and returned to their ships. The 226 planes that continued consisted of 95 Hellcat fighters (some carrying 500-pound bombs), 54 Avenger torpedo bombers (only a few carrying torpedoes, the rest four 500-pound bombs) and 77 dive bombers (51 Helldivers and 26 Dauntlesses). The TF 58 aircraft arrived over the Japanese fleet just before sunset. The 35 or so fighters Ozawa was able to put up were overwhelmed by the 226 incoming aircraft of Mitscher's attack. While the few Japanese aircraft were often skillfully handled and the Japanese anti-aircraft fire was intense, the U.S. planes were able to press in on the attack. The first ships sighted by the U.S. strike were oilers, 30 miles (48 km) before the carrier groups. The strike group from Wasp, more concerned with their low fuel levels than with finding the more important Japanese carriers and battleships, dived on the tankers. Two of these were damaged so severely that they were later scuttled, while a third was able to put out fires and get underway. The carrier Hiyō was attacked and hit by bombs and aerial torpedoes from four Grumman TBF Avengers from Belleau Wood. Hiyō was set afire after a tremendous blast from leaking aviation fuel. Dead in the water, she sank stern first, with the loss of 250 officers and men. The rest of her crew, about one thousand, were rescued by Japanese destroyers. The carriers Zuikaku, Junyō and Chiyoda were damaged by bombs.
== Prospects == Global wild fisheries are in decline, with valuable habitat such as estuaries in critical condition. The aquaculture or farming of piscivorous fish, like salmon, does not help the problem because they need to eat products from other fish, such as fish meal and fish oil. Studies have shown that salmon farming has major negative impacts on wild salmon, as well as the forage fish that need to be caught to feed them. Fish that are higher on the food chain are less efficient sources of food energy. Apart from fish and shrimp, some aquaculture undertakings, such as seaweed and filter-feeding bivalve molluscs like oysters, clams, mussels and scallops, are relatively benign and even environmentally restorative. Filter-feeders filter pollutants as well as nutrients from the water, improving water quality. Seaweeds extract nutrients such as inorganic nitrogen and phosphorus directly from the water, and filter-feeding mollusks can extract nutrients as they feed on particulates, such as phytoplankton and detritus. Some profitable aquaculture cooperatives promote sustainable practices. New methods lessen the risk of biological and chemical pollution through minimizing fish stress, fallowing netpens, and applying integrated pest management. Vaccines are being used more and more to reduce antibiotic use for disease control. Onshore recirculating aquaculture systems, facilities using polyculture techniques, and properly sited facilities (for example, offshore areas with strong currents) are examples of ways to manage negative environmental effects.
bacterial and mitochondrial N-formyl peptides and thereby initiates innate host immune responses. various synthetic N-formyl and non-formylated peptides that show distinguishing differences from those that interact with FPR2 and FPR3. T20/DP178 & T21/DP107, N-acetylated polypeptides derived from the gp41 HIV-1 envelope protein. This interaction is of unknown physiological significance although peptide T20/DP178 is a licensed anti-retrovirus agent (pentafuside) termed Enfuvirtide which acts at the level of HIV-target cell fusion and is used clinically to treat HIV-1 infection). Annexin A1 (also termed ANXA1 and lipocortin 1) and its N-terminal peptides (Ac2–26 and Ac9–25). At low concentrations, these agents stimulate neutrophils to raise cytosolic Ca2+ levels and thereby activate Ca2+-dependent signaling pathways; however, they do not fully activate the MAPK pathway but rather leave the neutrophil desensitized (i.e. unresponsive) to chemokine IL-8. At high concentrations, in contrast, the agents fully activate neutrophils and are potent pro-inflammatory stimulants.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.